From Health Affairs Today <[email protected]>
Subject Black Patients Remain Inadequately Represented In Clinical Trials For Drugs
Date March 18, 2022 8:00 PM
  Links have been removed from this email. Learn more in the FAQ.
  Links have been removed from this email. Learn more in the FAQ.
Podcast: The Role of Private Equity In Health Care
 ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌

Problems viewing this email?

View Message In Browser

Friday, March 18, 2022 | The Latest Research, Commentary, And News From
Health Affairs

Dear John,

****On March 28, Health Affairs Editor-in-Chief Alan Weil will interview
Carole Johnson
, the
administrator for the Health Resources and Services Administration
(HRSA), for the next installment of Health Affairs' virtual Policy
Spotlight series. Register now
.

Clinical Trial Representation

In 2015 the Food and Drug Administration launched a plan aimed at
improving the diversity of participants in clinical trials and the
transparency of trial results for newly approved drugs.

In their article featured in this month's issue of Health Affairs,
Angela Green and colleagues report that the initiative did not improve
representation of Black relative to White participants
.

Further, only 20 percent of studies reporting results after the plan
went into effect met a requirement to include race-specific reporting of
benefits and side effects.

Given the plan's failure, Green and coauthors write, "The FDA should now
consider setting minimum thresholds for diverse inclusion [...] so that
trial participants mirror disease demographics and trials generate
adequate data specific to patients from diverse racial and ethnic
groups."

For more content about how race affects health research revisit the
February 2022 theme issue of Health Affairs, Racism & Health
.

Order The March Issue

[link removed]

Elsewhere At Health Affairs

Today in Health Affairs Forefront, Amit Jain and coauthors explore the
impact of the Maryland All-Payer Model

(MD-APM) on Medicare Advantage entry and proliferation in the state.  

Also, Health Affairs is accepting applications

to the Health Affairs Podcast Fellowship Program through March 31.
Listen to the Health Affairs Pathways
podcast to
see what the latest cohort of Fellows produced.

[link removed]

The Role Of Private Equity In Health Care

Listen to Health Affairs' Kathleen Haddad and Rob Lott discuss the role
of private equity in health care service lines.

Listen Here

Daily Digest

Despite The FDA's Five-Year Plan, Black Patients Remain Inadequately
Represented In Clinical Trials For Drugs

Angela K. Green et al.

Medicare Advantage And The Maryland All-Payer Model

Amit Jain et al.

Podcast: The Role Of Private Equity In Health Care

Robb Lott and Kathleen Haddad

 

[link removed]

[link removed]

 

[link removed]

 

[link removed]

 

[link removed]

 

mailto:[email protected]

About Health Affairs

Health Affairs is the leading peer-reviewed journal
at the intersection of health,
health care, and policy. Published monthly by Project HOPE, the journal
is available in print and online. Late-breaking content is also found
through healthaffairs.org , Health Affairs Today
, and Health Affairs Sunday
Update .  

Project HOPE is a global health and
humanitarian relief organization that places power in the hands of local
health care workers to save lives across the globe. Project HOPE has
published Health Affairs since 1981.

Copyright © Project HOPE: The People-to-People Health Foundation, Inc.

Health Affairs, 1220 19th Street, NW, Suite 800, Washington, DC 20036, United States

Privacy Policy

To unsubscribe from this email, click here
.
_________________

Sent to [email protected]

Unsubscribe:
[link removed]

Health Affairs, 1220 19th Street, NW, Suite 800, Washington, DC 20036, United States
Screenshot of the email generated on import

Message Analysis